Abstract
Stuttering is a speech disorder that affects one-percent of all adults and much has been learned recently of its neurologic correlates. Stuttering has been associated with excessive cerebral activity of the neurotransmitter, dopamine. Pharmacologic research has suggested that older generation dopamine antagonist (i.e. "typical antipsychotic") medications improve stuttering symptoms, but are associated with poorly tolerated adverse effects. The purpose of this study was to compare the efficacy and tolerability of olanzapine, a novel dopamine antagonist (or "atypical antipsychotic"), versus placebo in the treatment of adult developmental stuttering. Twenty-four adults who stutter participated in a twelve-week, randomized, double-blind, placebo-controlled trial conducted at two separate sites. Subjects received either olanzapine (2.5 mg titrated to 5 mg) or matching placebo. Subjects were rated on an objective measure of stuttering severity (SSI-3), a clinician based global impression (CGI), and a subject-rated self-assessment of stuttering (SSS). Subjects were also monitored for potential side-effects. Twenty-three of the twenty-four subjects enrolled in the trial successfully completed the full course of the study. Olanzapine wa...Continue Reading
Citations
Jul 11, 2009·Journal of Human Genetics·Jie LanWei Wang
Nov 10, 2011·Folia Phoniatrica Et Logopaedica : Official Organ of the International Association of Logopedics and Phoniatrics (IALP)·Shelly Jo Kraft, Ehud Yairi
Jan 21, 2012·Neuroreport·Christian MontagMartin Reuter
Jul 4, 2013·Daru : Journal of Faculty of Pharmacy, Tehran University of Medical Sciences·Javad Alaghband-RadPadideh Ghaeli
Oct 7, 2016·PloS One·Pierpaolo BusanPiero Paolo Battaglini
Aug 14, 2019·Proceedings of the National Academy of Sciences of the United States of America·Tae-Un HanDennis Drayna
Jul 16, 2008·Journal of Clinical Psychopharmacology·Nancy L TranGlyndon D Riley
Jan 31, 2008·American Journal of Speech-language Pathology·Timothy Meline, William E Harn
Jul 29, 2008·Journal of Speech, Language, and Hearing Research : JSLHR·Andrew StuartPaul W Vos
Apr 8, 2015·The European Journal of Neuroscience·Laura E Matheson, Jon T Sakata
Jun 15, 2018·Journal of Clinical Psychopharmacology·Sahil MunjalStephen Ferrando
May 16, 2007·The American Journal of Hospice & Palliative Care·Phuc H Duong, Gilbert B Zulian
Jan 16, 2010·Journal of Clinical Psychopharmacology·Gerald MaguireGlyndon Riley
Nov 26, 2009·Journal of Psychiatric Practice·Glenn CatalanoDavid A Kahn
Dec 3, 2014·Frontiers in Human Neuroscience·Anna Craig-McQuaideElina Tripoliti
Jul 22, 2009·Clinical Neuropharmacology·Pierpaolo BusanGiovanna Pelamatti
Apr 16, 2020·Frontiers in Neuroscience·Gerald A MaguireTroy L Kurz
Dec 12, 2020·Frontiers in Human Neuroscience·Per A Alm
May 13, 2021·Nature Communications·Lei XiaoTodd F Roberts
Jun 8, 2021·Brain and Language·Ariana Z TurkShahriar SheikhBahaei
Aug 31, 2021·Frontiers in Human Neuroscience·Pierpaolo BusanGianluca Campana